According to a new study by researchers at Washington University School of Medicine in St. Louis, delaying lung cancer surgery for more than 12 weeks from the date of diagnosis with CT…
Tag: Lung Cancer News
FDA Approves Rybrevant for Certain Patients with Non-Small Cell Lung Cancer
Lung cancer is a complex disease, accounting for almost 25% of all cancer deaths. The Food and Drug Administration (FDA) has approved Rybrevant for treatment of adults with non-small cell lung cancer…
Study Investigates on Rare Genetic Variants that Increase Lung Cancer Risk
In US, lung cancer is one of the leading causes of cancer deaths among both men and women. The risk of this disease lies mainly with lifestyle factors like smoking and environmental…
Detecting Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients
Non-small cell lung cancer is the most prevalent form of lung cancer and accounts for more than 80% of all lung cancer cases. Circulating tumor cells (CTCs) lead to metastases and often…
FDA Approves Libtayo as Monotherapy for Advanced NSCLC
Lung cancer is one of the leading causes of cancer-related deaths worldwide. In the year 2020, an estimated 225,000 new cases were diagnosed in the United States. Also, approximately 84% of all…
Lung Cancer Myth Busting: Long Term Use of Face Mask Cause Lung Cancer
The health officials all around the world encourage people to wear masks to slow down the spread of COVID 19 but according to a Facebook post, it claims that masks can give…
NICE Recommends Keytruda Plus Chemo for NSCLC Treatment
National Institute for Health and Care Excellence (NICE) has recommended Keytruda, alongside a combination of pemetrexed and platinum chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC). This combination is recommended…
Amgen Drug, Sotorasib, Shows Success in Phase II Trial against Non-Small Cell Lung Cancer
An Amgen Inc. lung cancer drug, sotorasib, targets an aggressive genetic mutation called KRAS. In the Phase II trial, this drug has shown to provide durable clinical benefit with pretreated non-small cell…